1 Y-27632, another well-established ROCK inhibitor, has been widely used to study the biological and pharmacological functions of ROCK in vitro and in vivo. [1] [2] [3] A majority of studies have
shown that ROCK functions as a positive regulator in tumor cell growth, migration, metastasis and survival. 1 For instance, Y-27632 decreased breast cancer cell invasion/migration in vitro and metastasis in vivo 4 ; Y-27632 was reported to reduce invasive potential of ovarian cancer 5, 6 and colon cancer cells 7 ; Y-27632-was shown to suppress progression of hepatocellular carcinoma through negative regulation of its proliferation and migration. 8 In contrast to these beneficial findings, other studies have shown that ROCK inhibitors can stimulate tumor functions. Y-27632 was reported to increase migration and invasion of MCF-7 breast cancer cells, to enhance the migration of SW480 colon cancer cells and to promote the proliferation of both colon and pancreatic cancer cells. [9] [10] [11] [12] Taken together, depend on cell type, cell-context and the involved microenvironments.
Melanoma is the most dangerous and aggressive skin cancer. 13 Finding a cure for metastatic melanoma remains a challenge, although recent immunotherapeutic applications appear promising. [13] [14] [15] The mutation of BRAF gene (BRAF V600E ), a major growth driver, occurs in 65% of aggressive melanomas. 16 The effect of ROCK inhibitors on melanoma formation has not been studied in detail. Whatever we know about the ROCK inhibitor effect on melanoma was learned from studies of mouse B16 melanoma cells; these studies suggest that the inhibition of ROCK by Y-27632 could block melanoma cell proliferation and migration in vitro and in vivo [17] [18] [19] [20] ; however, the underlying molecular mechanism remains unclarified. Therefore, we investigated the effect of Y-27632 on human melanoma cells. Interestingly, we found that Y-27632 actually enhances both human melanoma cell growth and migration in vitro and in vivo, rather than blocking it, as previously reported. We found that the enhancement of Y-27632 depends on the mutation status of the BRAF gene of melanoma through increased AKT activity.
| MATERIALS AND METHODS

| Melanoma cell culture and drug treatments
All melanoma cells and primary melanocytes (HEM) were cultured in DMEM supplemented with 10% FBS and .1% penicillin/streptomycin.
Y-27632 (Sigma Chem Co., St. Louis, MO, USA) was dissolved in the distilled H 2 O to make 10 mmol/L of stock solution; cells were treated with 10 μmol/L Y-27632.
| Cell proliferation assay
Melanoma cells were seeded in 96-well plates at a density of 7.5 × 10 4 cells/mL treated with or without Y-27632 and collected at the indicated time. The proliferation was determined using a cell counting kit-8 (CCK8) as previously described. 
| Wound healing and migration assay
In vitro wound healing was studied as previously described. 22 In brief, melanoma cells were seeded onto 6-well plates, grown to washed, and then stained with .1% crystal violet (Sigma-Aldrich). The number of cells that had migrated into the lower chamber was counted in 6 randomly selected high-power microscopic fields.
| ROCK activity assay
The activity of ROCK was measured by using an ELISA kit (Cell Biolabs, STA-416, San Diego, CA, USA) and followed the manufacturer's instructions. Briefly, melanoma cells with different conditions as described in the figure legends were lysed and the cell lysates were placed in MYPT-1-precoated wells and incubated for 1 hour at 30°C
and anti-Phospho-MYPT-1 (Thr696) antibody was added for another 1 hour. Then, the HRP-conjugated secondary antibody was added into the solution. After another 1-hour incubation, the plates were washed, and the substrate solution was added for incubation of 10 minutes. Absorbance at 450 nm reflected the relative amount of ROCK activity in the sample, which was calculated relative to the total protein content of each sample.
| Western blot analysis
The Western blots were carried out according to the standard 
| In vivo tumor formation
Eight-week-old nude/nude mice (Charles River Laboratories, Wilmington, MA, USA) were randomly assigned to the control group (PBS only; N = 3 mice) or drug treatment groups (Y-27632 in PBS; N = 3 mice). One million UACC257 cells were injected subcutaneously into the backside skin of mice as described previously 23 , and each mouse received 6 injections. Then, Y-27632 (10 mg/kg) was intraperitoneally injected, and administrated 3 times a week for 2 weeks. At 3 weeks after grafting, mice were killed, and the resultant tumors were collected and weighed.
| Ethics statement
The animal study was approved by the ethics committee of Stomato- 
| RESULTS
| ROCK inhibitor promoted melanoma cell growth and migration
To test the effect of Y-27632 on melanoma cell growth, we treated melanoma cell line UACC257 with 10 μmol/L Y-27632. In contrast to the previous report, we found that Y-27632 did not inhibit UACC257 growth but enhanced it, as measured by the CCK8 proliferation assay ( Figure 1A ). Because this result was inconsistent with
the previous reports, we tested another human melanoma cell line, UACC62, in the same way; once again, we found the same result 
| ROCK inhibitor promotes BRAF-mutant melanoma cell growth and migration
The effect of Y-27632 on melanoma cell growth and migration was inconsistent with a previous report which showed that Y-27632
inhibited the proliferation and migration of B16F1 mouse cells, a widely used mouse melanoma cell line. 18 Therefore, we checked whether Y-27632 produced the same effect on B16F1 cells in our culture system. We treated B16F1 with 10 μmol/L of Y-27632 and found that our result agreed with the previous finding: The treatment of Y-27632, indeed, blocked B16F1 cell growth ( Figure 3A) and migration ( Figure 3B ). This result suggested that the effect of ROCK inhibitor is likely cell-specific. Recognizing the importance of BRAF mutation to melanoma formation, we noticed that both Figure 3C ).
Second, we found that Y-27632 inhibited the growth of normal human primary melanocytes (HEM) ( Figure 3D ). Finally, we tested another BRAF-mutant melanoma cell M14, and, again, we found that Y-27632 could enhance cell migration ( Figure S1 ). Interestingly, we did not observe a significant difference in ROCK activity between BRAF wild-type and mutant cells at normal culture conditions (Figure S2) . In summary, these data suggest that the effect of Y-27632 on melanoma cell growth and migration depends on the mutant status of BRAF gene. All experiments were carried out at least 3 times, and the error bars represent the mean ± standard deviation; a t test was used for statistical analysis when comparing the treated cells with the corresponding control group. P value as indicated with "*": ** P < .01, * P < .05
| In vivo ROCK inhibitor administrated increases the formation of BRAF-mutated melanoma
The previous study showed that Y-27632 reduced murine B16F1 tumor cell growth in vivo. 17 To verify that Y-27632 can promote BRAF-mutated melanoma cell growth in vivo, we subcutaneously injected UACC257 cells into the back skin of nude/nude mouse; 6 injections were delivered into each mouse, 1 million UACC257 cells . Cells were collected at 24 and 48 h after treatment for proliferation assay by CCK8 kit. *Indicates P < .005 when comparing with Y-27632-treated group. E, The in vitro wound healing assay was carried out with UACC257 melanoma cells in the presence of Y-27632 and combined with inhibitors wortmannin (Wort), PLX4032 (PLX) and Sorafenib (So), with DMSO as control. The relative healing percentage is shown. *Indicates P < .05 when comparing healing percentage of 2 groups as labeled. All experiments were carried out 3 times, and the error bars represent the mean ± standard deviation. A t test was used for statistical analysis; P value as indicated with "*"
suppressor gene PTEN, leading to the upregulation of ATK activity. 29, 30 AKT has been shown to phosphorylate RAF, inhibit the RAF-MEK-ERK pathway, and cause reduced ERK activation in normal cells, [31] [32] [33] and the downregulation of ERK pathway possibly further reduces the AKT activation as a feedback mechanism. 33 We speculated that the feedback inhibition of ERK on AKT activity is deregu- 
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